NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM

BACKGROUND: Plexiform neurofibromas (PNs) can cause significant morbidity. In this phase 2 study, we assessed imaging and functional outcomes to the MEK-inhibitor Binimetinib in pediatric patients with PNs. METHODS: Children (age 1–17 years) with PN that were progressive or causing significant morbi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Mueller, Sabine, Reddy, Alyssa T, Dombi, Eva, Allen, Jeffrey, Packer, Roger, Clapp, Wade, Goldman, Stewart, Schorry, Elizabeth, Tonsgard, James, Blakeley, Jaishri, Ullrich, Nicole J, Gross, Andrea, Walsh, Karin, Thomas, Coretta, Edwards, Lloyd, Prados, Michael, Korf, Bruce, Fisher, Michael J
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Neurofibromatosis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715338/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.619
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars